Growth Promoting Effect of Recombinant methionyl-Growth Hormone in Children with Chronic Renal Failure |
Heon Seok Han1, Yong Choi2, Hyung Ro Moon2 |
1Department of Pediatrics, Chonbuk National University Medical School, Cheongju, Korea 2Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea 2Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea |
만성 신부전 환자에서 성장 호르몬의 성장 촉진에 관한 연구 |
한헌석1, 최용2, 문형로2 |
1충북대학교 의과대학 소아과학교실 2서울대학교 의과대학 소아과학교실 2서울대학교 의과대학 소아과학교실 |
|
|
Abstract |
The authors studied the growth-promoting effect of yeast-derived methionyl-hGH in short statured children with uremic chronic renal failure.
The subjects were prepubertal chronic renal insufficient patients whose height standard deviation scores were below -2.0. Two boys and two girls participated in this study. Chronic renal insufficiency was the only cause for the short stature.
HGH was given to the subjects in dose of 0.75 U/kg/wk subcutaneously in three divided doses for the first six months, and then in six divided doses for the next six months. The height, weight, complete blood count and blood chemistries were checked every 3 months, and bone age, thyroid functions, IGF-1 and growth hormone antibody were tested every 6 months.
The mean height SDS before treatment, at 6 months, and at 12 months of therapy was -4.43, -4.42 and -4.05, respectively. The height velocity before therapy, at 6 months and at 12 mo of therapy was 2.68, 5.43 and 5.90 cm/yr, respectively. The height velocity differences were -2.05 before therapy, +1.43 at 6 mo, +1.60 cm/yr at 12 mo of therapy.
The mean bone age advancement was 0.9 yr in a year of therapy. The growth hormone antibody was not detected during therapy with the preparation.
These results suggest that administration of yeast-derived methiony-hGH is effective in promoting linear growth for the short statured uremic prepubertal children. |
Key Words:
Human growth hormone, Chronic renal failure, Short stature |
|